MDCX Medicus Pharma Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1997296 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-42.4%
TTM EPS YoY160.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-415.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets172.2%
Debt / equity—
Current ratio0.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-101.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.95M | $4.91M | $2.70M | $2.59M | $1.68M | $1.44M | $2.01M | $1.37M |
| SG&A expense | $2.51M | $6.57M | $5.89M | $5.20M | $5.02M | $4.58M | $3.12M | $2.22M |
| Operating income | -$14.46M | -$11.48M | -$8.60M | -$7.79M | -$15.43M | -$6.02M | -$5.13M | -$3.59M |
| Interest expense | — | $205,638 | $374,712 | — | — | $0 | $0 | — |
| Net income | -$15.18M | -$11.62M | -$9.04M | -$15.07M | -$20.94M | -$6.18M | -$5.10M | -$3.54M |
| EPS (basic) | -11.64 | -0.21 | -0.31 | — | -56.18 | -0.43 | -0.42 | — |
| EPS (diluted) | -11.64 | -0.21 | -0.31 | — | -56.18 | -0.43 | -0.42 | — |
| Weighted avg. shares (diluted) | 1.30M | 55.06M | 29.54M | — | 372,633 | 14.28M | 12.24M | — |
| Banking | ||||||||
| Net interest income | -$712,652 | — | — | -$272,824 | $11,572 | $40,004 | — | $48,897 |
| Balance sheet | ||||||||
| Cash & equivalents | $5.02M | $15.17M | $6.37M | $8.71M | $8.66M | $9.67M | $3.98M | $4.16M |
| Current assets | $6.37M | $16.98M | $7.28M | $9.89M | $9.78M | $11.00M | $5.09M | $5.38M |
| Total assets | $14.54M | $27.12M | $7.43M | $10.06M | $9.98M | $11.93M | $5.66M | $5.65M |
| Current liabilities | $9.74M | $10.84M | $5.95M | $9.94M | $10.66M | $8.54M | $3.34M | $2.31M |
| Short-term debt | — | — | $2.34M | $5.25M | $6.79M | $4.70M | — | $0 |
| Total liabilities | $25.03M | $28.84M | $6.00M | $10.02M | $10.78M | $8.69M | $3.51M | $2.51M |
| Shareholders' equity | -$10.54M | -$1.76M | $1.33M | -$67,554 | -$910,126 | $3.25M | $2.15M | $3.13M |
| Shares outstanding | 1.85M | 60.17M | 40.00M | 503,526 | 20.97M | 15.94M | 13.42M | 11.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.94M | -$6.98M | -$8.97M | -$6.61M | -$6.76M | -$5.47M | -$3.94M | -$3.19M |
| Investing cash flow | — | — | — | $0 | — | — | — | $0 |
| Financing cash flow | $3.89M | $25.53M | $6.83M | $6.65M | $10.37M | $11.16M | $3.76M | $2.05M |
| Stock-based compensation | $131,775 | $1.41M | $599,306 | $429,712 | $852,757 | $117,448 | $112,277 | $91,724 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.